Chronic low-grade inflammation involving adipose tissue likely contributes to the metabolic consequences of obesity. The cytokine interleukin (IL)-33 and its receptor ST2 are expressed in adipose tissue, but their role in adipose tissue inflammation during obesity is unclear.
O besity is a consequence of many complex factors, including increased calorie consumption and reduced physical activity. Many studies also implicate chronic low grade inflammation in the interplay between obesity and metabolic complications (reviewed elsewhere 1 ). During obesity, white adipose tissue (WAT) is infiltrated by immune cells, such as macrophages and T cells, [2] [3] [4] which, along with the adipocytes themselves, secrete a variety of proinflammatory cytokines and chemokines (reviewed elsewhere 5 ). Recent studies demonstrate that the infiltrating T cells display a Th1 pattern of activation with enhanced interferon-␥ production, 6 and that an imbalance may exist in obese adipose between dominant Th1 responses and reduced Treg or Th2 responses. [7] [8] [9] This, in turn, leads to macrophage recruitment and a switch from a protective alternatively activated (M2) macrophage to a classically activated (M1) proinflammatory phenotype. 7, 10 Several observations indicate a role for the interleukin (IL)-1 family of cytokines in obesity. IL-1 inhibits adipocyte differentiation, stimulation of lipolysis and induces the development of an insulin resistant phenotype. 11 Adipocytes also produce IL-1 receptor antagonist (IL-1Ra), and levels of IL-1Ra are strongly elevated in the serum of obese patients and highly correlated with insulin resistance. 12 IL-18 concentrations are increased in serum of individuals with obesity and type 2 diabetes, 13 but absence of IL-18 or IL-18R or the overexpression of IL-18 binding protein in genetically modified mice, leads to abnormalities characteristic of the metabolic syndrome. 14 Furthermore, inhibition of IL-1-associated pathways in patients with diabetes improved glycemia and ␤-cell secretory function and reduced markers of systemic inflammation. 15, 16 These findings highlight the therapeutic potential of targeting IL-1 family of cytokines in type 2 diabetes. IL-33 is a newly identified member of the IL-1 cytokine family that induces production of Th2 cytokines, 17 by interacting with a heterodimeric receptor comprising ST2 and IL-1 receptor accessory protein (IL-1Racp). 18 The ST2 gene encodes 2 protein isoforms: ST2L, a transmembrane receptor; and a secreted soluble (sST)2 form, which can serve as a decoy receptor for IL-33. Several lines of evidence suggest a role for the IL-33/ST2 pathway in cardiovascular biology.
Serum elevations of sST2 predict mortality and heart failure in patients with acute myocardial infarction. 19, 20 Furthermore, we have demonstrated that the IL-33/ST2 pathway has a protective role in the progression of atherosclerosis via the induction of Th2 cytokines and anti-oxLDL antibodies. 21 More recently, IL-33 and ST2 were shown to be expressed in human adipose tissue. 22 In this study, we show that IL-33 has clear protective effects against obesity and type 2 diabetes. IL-33 induced Th2 cytokines in WAT, and the polarization of WAT macrophages toward an M2 alternatively activated phenotype with reduced adipose mass and fasting glucose. Taken together, these results demonstrate a novel protective role for IL-33/ ST2 during obesity and suggest that induction of Th2 cytokines and alternative macrophage polarization by manipulating IL-33 expression may be a useful therapeutic strategy for treating or preventing type 2 diabetes in obese patients.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Animals
Male obese (ob/ob) mice (B6v-Lep ob/J) were purchased from The Jackson Laboratory at 5 weeks old and allowed to acclimatize for 1 week. These mice were fed normal diet and at 6 weeks randomly grouped and injected intraperitoneally 3 times per week for 3 weeks with control PBS or recombinant IL-33 (Biolegend, 2 g/injection). Male BALB/c wild-type (WT) mice and BALB/c ST2 Ϫ/Ϫ mice were bred in-house in a pathogen-free facility and fed either normal diet or a high fat diet (HFD) (0.15% cholesterol and 21% lard, Special Diet Services) ad libitum from 6 weeks of age. All animal experiments complied with United Kingdom Home Office guidelines.
Statistical Analysis
All data are meansϮSEM. Statistics were performed using unpaired Student's t tests or ANOVA with GraphPad Prism Software.
Results

IL-33 Induces Th2 Cytokines and Chemokines in WAT Cultures In Vitro
To establish the cellular localization of ST2 expression in WAT, we carried out flow cytometric double immunostaining of collagenase digested murine epididymal stromal vascular fraction (SVF) cells. Both F4/80 ϩ macrophages and F4/80 Ϫ cells expressed ST2 ( Figure 1A) , indicating the potential for multiple cell types in WAT to respond to IL-33. We then examined the effect of IL-33 treatment on cytokine and chemokine secretion from murine SVF cells cultured from epididymal WAT (eWAT) of WT and ST2 Ϫ/Ϫ mice in vitro. Addition of IL-33 to SVF cultures from WT but not ST2 Ϫ/Ϫ mice induced secretion of the cytokines IL-5, IL-6, IL-13 ( Figure 1B) , and chemokines MCP-1, MIP-1␣, and KC ( Figure  1C ). Macrophage depletion markedly reduced, but did not abolish, IL-33-induced expression of IL-6, MCP-1 and KC ( Figure 1D ). However, IL-33-induced expression of IL-13 and MIP-1␣ were completely abolished by macrophage depletion. In contrast, IL-5 expression was unaffected by macrophage depletion. Intracellular staining in IL-33-treated SVF cultures dem-onstrated IL-6 expression in both F4/80 ϩ and F4/80 Ϫ cells ( Figure 1E ). These studies indicate that IL-33 can act on both macrophages and other F4/80 Ϫ cells in the SVF (eg, preadipocytes) to induce cytokine and chemokine production.
IL-33 Induces Changes in Lipid Storage and Expression of Metabolic Genes in WAT Cultures In Vitro
To further investigate the mechanisms of action of IL-33 in WAT, we examined the effect of IL-33 on adipocyte differentiation in vitro. Addition of IL-33 for 7 days during the differentiation process of murine SVF cells significantly inhibited lipid accumulation (oil red O staining) ( Figure 2A ), and this effect was absent in cells from ST2 Ϫ/Ϫ mice ( Figure  2B ). IL-33 treatment also reduced the mRNA expression of C/EBP␣ (CAAT enhancer-binding protein-␣), SREBP-1c (sterol regulatory element-binding protein 1c), liver X receptor (LXR)␣, LXR␤, and PPAR␥, all associated with lipid metabolism and adipogenesis ( Figure 2C ). Furthermore, we used a mouse proteome array to simultaneously examine the expression of 38 obesity-related proteins in the supernatants of IL-33-treated (100 ng/mL) SVF cultured cells ( Figure 2D and 2E). The expression of molecules shown to be protective against obesity, such as FGF-acidic, FGF-21, IGFBP-1, IL-10, IL-11, and RAGE, [23] [24] [25] [26] were Ͼ2-fold increased by IL-33, whereas expression of Resistin, which induces insulin resistance, 27 was Ͻ2-fold decreased by IL-33. Taken together, these results indicate that IL-33 has potent effects on adipocyte differentiation and expression of metabolic genes and adipokine proteins in SVF cultures and support a role for IL-33 in the metabolic regulation of WAT.
Effect of Exogenous IL-33 on Metabolic Parameters In Vivo
To directly investigate the effect of IL-33 on obesity in vivo, we treated spontaneously obese (ob/ob) mice with PBS or recombinant IL-33. IL-33 did not affect the final body weight of ob/ob mice ( Figure 3A ; PBS-treated, 41.4Ϯ0.7 g versus IL-33-treated, 40.1Ϯ0.7 g) or food intake ( Figure 3B ), but eWAT weight was decreased by 9.9% ( Figure 3C and 3D ). Furthermore, IL-33-treated mice displayed a 13% decrease in body fat (AUClipid) and a 17% increase in fat-free mass PϽ0.001). In addition, IL-33 treatment significantly reduced total serum cholesterol (4.0Ϯ0.1 versus 3.3Ϯ0.1 mmol/L), but did not affect high-density lipoprotein cholesterol (1.4Ϯ0.1 versus 1.1Ϯ0.1 mmol/L), or triglyceride (0.6Ϯ0.1 versus 0.7Ϯ0.1 mmol/L) concentrations ( Figure 3H ). Weekly analysis of fasting blood glucose levels in IL-33treated ob/ob mice demonstrated lower levels than the PBStreated controls ( Figure 3I) . Surprisingly though, no significant difference in serum insulin levels was found ( Figure 3J ), suggesting that insulin secretion was not altered by IL-33, nor responsible for the lowered fasting glucose levels. IL-33-treated mice also showed significantly lower glucose levels after a glucose load ( Figure 3K ). To investigate whether altered insulin sensitivity explains the changes in glucose levels and tolerance we carried out an insulin tolerance test in the mice at week 7 and 9. Improved insulin sensitivity was found in IL-33-treated mice at week 7 but not at week 9 ( Figure 3L ), when perhaps some tolerance to the effects of IL-33 were evident.
IL-33 Induces Accumulation of Th2 Cytokines in Serum and Th2 Cells in WAT
We analyzed changes in circulating cytokines and adipokines following IL-33 treatment in serum of ob/ob mice. IL-33- treated mice produced markedly more IL-5, IL-6, IL-10 and IL-13 ( Figure 4A ) than PBS-treated mice, but no significant change in TNF␣, MCP-1, Resistin or tPAI-1 (data not shown). Furthermore, given the large increase in the chemokines MCP-1, MIP1␣ and KC released by IL-33-treated SVF cultures we assessed inflammatory cell infiltration into eWAT from PBS versus IL-33-treated ob/ob mice using the markers CD45 (pan-leukocytes) and F4/80 (macrophages). IL-33 induced the accumulation of CD45 ϩ F4/80 Ϫ cells in eWAT. Further analysis revealed these cells to be 75% CD3 ϩ T cells ( Figure 4B ). CD3 ϩ T cells were also found in eWAT of PBS-treated mice but at a lower frequency (61%). Expression of ST2, a marker for a subpopulation of Th2 cells, 28 was increased in both CD45 ϩ F4/80 ϩ cells and in CD45 ϩ F4/80 Ϫ cells (75% of which are CD3 ϩ ) ( Figure 4C ), indicating that IL-33 treatment has induced local accumulation of Th2 cells. Consistent with this, eWAT from IL-33-treated ob/ob mice contained more IL-5-producing CD45 ϩ F4/80 Ϫ and CD45 ϩ F4/80 ϩ SVF cells than those from PBS-treated mice ( Figure 4D ).
Accumulation of Alternatively Activated Macrophages (M2) in WAT of Mice Treated With IL-33
Immunohistochemistry on eWAT sections taken from IL-33treated ob/ob mice demonstrated F4/80 ϩ cells accumulating in clusters around adipocytes ( Figure 5A ). CD45 ϩ F4/80 ϩ SVF cells were significantly increased in IL-33-treated mice compared to PBS-treated mice ( Figure 5B and 5C ). To investigate the phenotype of these macrophages, we stained CD45 ϩ F4/80 ϩ cells with TLR2 (M1 marker) and CD206 (mannose receptor, M2 marker) antibodies. As shown in Figure 5B and 5C, PBS-treated ob/ob mice contained a higher frequency of TLR2 ϩ macrophage and lower percent of CD206 ϩ macrophages. In contrast, IL-33-treated ob/ob mice contained a higher frequency of CD206 ϩ macrophages but lower percent of TLR2 ϩ macrophages. Taken together, these results suggest that IL-33 treatment increases the accumulation of macrophages in WAT and has substantial influence over their polarization toward an M2 phenotype.
Expression of Hepatic M2 Macrophage Genes in Mice Treated With IL-33
We examined the metabolic changes and gene expression in the liver of obese mice treated with IL-33. IL-33 treatment did not affect liver weight (3.6Ϯ0.2 versus 3.3Ϯ0.2 g), serum levels of the aminotransferase enzymes AST (285.8Ϯ30.4 versus 279.6Ϯ33.6 U/L) or ALT (27.6Ϯ12.0 versus 28.2Ϯ6.4 U/L), or liver histology (data not shown). Additionally, expression of the phosphoenolpyruvate carboxykinase (PCK-1) gene, involved in gluconeogenesis in liver, was not altered by IL-33 treatment (mean expression, 1.22Ϯ0.08 versus 1.25Ϯ0.09), indicating that downregulation of PCK-1 is not likely responsible for the glucose lowering actions of IL-33. However, we did not investigate the expression of other genes involved in gluconeogenesis (eg, glucose-6- phosphatase) and could not exclude that their expression was altered in response to IL-33. Expression levels of SREBP-1c, FAS (fatty acid synthase), LXR␣, LXR␤, and PGC-1␣ (PPAR␥ coactivator-1␣) were similar in PBS-and IL-33-treated mice (data not shown). In contrast, IL-33 strongly enhanced the mRNA expression of M2 markers in liver, including L-arginase (Arg1), Ym1 (Chi313), and RELM/Fizz (retnla [resistin-like molecule/found in inflammatory zone]), with no significant change in expression of inducible nitric oxide synthase (a M1 marker) ( Figure 6A and 6B ). Furthermore, expression of peroxisome proliferator-activated receptor (PPAR)-␦, associated with M2 macrophage polarization, 29 was increased in livers of IL-33-treated mice ( Figure 6C ). Consistent with the findings in WAT, these results suggest that IL-33 also increases polarization of liver macrophages/Kupffer cells toward an M2 phenotype.
Endogenous ST2 Regulates Body Weight, Adipose Tissue, and Glucose Homeostasis
To investigate the physiological significance of basal endogenous IL-33/ST2 signaling in metabolism we measured metabolic parameters, body weight/composition of WT and ST2 Ϫ/Ϫ mice over 24 weeks of feeding either normal diet or HFD. On normal diet body weight of ST2 Ϫ/Ϫ mice was similar to that of the WT mice ( Figure 7A ). Mice on the BALB/c background are generally resistant to diet-induced obesity; however, at 24 weeks of age body weight of ST2 Ϫ/Ϫ mice fed HFD was increased by on average 11.5% compared to WT controls ( Figure 7A; PϽ0.05 ). Furthermore, weight of eWAT was increased in ST2 Ϫ/Ϫ mice fed either HFD (2.0 versus 1.3g, PϽ0.01) or normal diet (0.62 versus 0.31g, PϽ0.0001) when compared to WT controls ( Figure 7B ). ST2 Ϫ/Ϫ mice displayed a 17% increase in percentage body fat (AUClipid) and a 9% decrease in FFM (AUCH 2 O), compared to WT controls ( Figure 7C and 7D) fed HFD at 24 weeks of age. However, serum total cholesterol, triglycerides, and high-density lipoprotein cholesterol were not different between WT and ST2 Ϫ/Ϫ mice (data not shown).
To investigate whether the obese phenotype in ST2 Ϫ/Ϫ mice fed HFD is mediated through effects on glucose homeostasis, we measured fasting insulin and glucose. Fasting serum insulin concentration was significantly lower at 24 weeks compared to WT controls ( Figure 7E ), but fasting glucose levels, measured every 2 weeks, were not different between ST2 Ϫ/Ϫ mice and WT controls ( Figure 7F ). However, at 24 weeks, ST2 Ϫ/Ϫ mice were more hyperglycemic in response to intraperitoneal glucose than WT controls ( Figure  7G ), but insulin responsiveness was not different ( Figure 7H) . These results suggest that ST2 Ϫ/Ϫ mice are not insulin resistant but may have impaired pancreatic insulin production in response to glucose overload. Taken together, these data demonstrate that ST2 signaling appears to play some role in controlling body weight gain and the regulation of WAT and glucose homeostasis. 
Discussion
In this study, we show for the first time that IL-33 treatment can modulate cytokine production and macrophage phenotype in WAT and liver and induce protective effects on body composition and glucose homeostasis.
Although IL-33 has already been shown to be expressed in adipose tissue, 22 the cellular source of IL-33 in adipose tissue is still unclear. However, recent studies have shown endothelial cells express IL-33 as a vascular alarmin, 30 and macrophages and fibroblasts in other tissues express IL-33. 31, 32 Therefore, multiple cell types in adipose tissue have the potential to produce IL-33. Treatment of ob/ob mice with IL-33 led to production of strong Th2 responses in WAT. Our findings agree with Kang et al, who have previously demonstrated that adipocytes can produce the Th2 cytokines IL-4 and IL-13, 33 which led to alternative activation of macrophages. Furthermore, recent work suggests that during obesity a relatively constant pool of Th2 fat-associated T cells fail to limit an expanding Th1 pool of proinflammatory cells and that Th2 cells exert protective functions in insulin resistance. 8 In addition, a recent study has documented the existence of a new population of cells, termed "natural helper cells," in fat, which are ST2 positive, respond to IL-33 and produce large amounts of Th2 cytokines, 34 though the role of these cells in obesity is not yet known. Therefore, IL-33 may exert its protective effects via an expansion of a Th2 pool of fat-associated T cells or natural helper cells and increased production of Th2 cytokines.
The significance of raised systemic levels of IL-6 in obesity is controversial. In humans, blood levels of IL-6 are elevated in obesity and correlate with adiposity and insulin resistance. 35 However, our results show that IL-33 has beneficial effects on metabolism despite an increase in circulating IL-6. It has previously been shown in mice that absence of IL-6 led to maturity onset obesity though a central action. 36 Furthermore, infusion of IL-6 in mice affected adipose insulin sensitivity but did not affect systemic glucose tolerance test or HOMA index. 37 Therefore, the effects of IL-6 in the context of metabolism may be species-dependent. In addition, IL-33 induced expression of several chemokines in WAT and an increase in the proportion of infiltrating macrophages into WAT of obese mice. Whereas MCP-1 is reported to recruit M1 macrophages and have detrimental effects on obesity and metabolism, 38 the IL-33-induced macrophages did not have a classic proinflammatory M1 phenotype. It is possible that M1 macrophages were recruited, which then switched to an M2 on encountering an IL-33-driven local Th2 environment in WAT. Consistent with this notion, IL-33 increased expression of M2 markers (CD206, Arginase 1, Ym1/ chitinase 3-like 3 and FIZZ/RELM, IL-10, and PPAR␦) in adipose tissue and liver. Two recent studies document that PPAR␦ plays a key role in alternative activation of resident macrophages in WAT and liver. 29, 33 Furthermore, deletion of PPAR␦ in macrophages led to impaired glucose tolerance and exacerbation of insulin resistance. In liver, Odegaard et al demonstrated that PPAR␦ is critical for maintaining an M2 phenotype of Kupffer cells and this leads to hepatic dysfunction and insulin resistance. 29 Alternatively activated M2 macrophages can regulate insulin resistance through the production of IL-10. This IL-10 can reverse the proinflammatory cytokine-induced activation of serine kinases, which phosphorylate IRS-1, thus inhibiting the action of insulin. 1, 10 It is thus likely that one of the mechanisms by which IL-33 treatment induces protective effects is by promoting Th2 cytokine synthesis leading to the preferential differentiation of M2 macrophages in both adipose and liver.
Investigation of the metabolic phenotype of ST2 Ϫ/Ϫ mice demonstrated that these mice have enhanced weight gain (11.5%) at 24 weeks of age on HFD and had more adipose tissue compared to WT controls, indicating a mature onset of obesity. However, the obese phenotype of the ST2 Ϫ/Ϫ mice may not be a severe as that seen with other cytokine/cytokine receptor knock out mice, especially as the ST2 phenotype was only seen with high fat feeding. On normal diet, IL-18 Ϫ/Ϫ mice were 18.5% heavier at 6 months, 14 and both IL-1R1 Ϫ/Ϫ and IL-6 Ϫ/Ϫ mice displayed weight deviation from WT at 5 to 6 months of age with 20% weight difference by 9 months. 36, 39 This comparatively smaller effect in the ST2 Ϫ/Ϫ mice may be a result of their BALB/c background, known to be more obesity resistant than the C57BL/6 background.
In summary, we report a novel function for IL-33 in obesity which is likely to be through the induction of the Th2 cytokines IL-5 and IL-13, which, in turn, can skew macrophages in adipose and liver from an M1 to M2 phenotype, and hence reduce the chronic inflammatory response associated with obesity. Many questions now arise from this work. IL-33 appears to have catabolic effects and experiments should be carried out to assess its effects on activity levels and energy expenditure, substrate utilization and metabolic rate. In addition, although we have clearly focused on the role of secreted IL-33, the nuclear expression of IL-33 in adipose may also indicate a separate function that is not dependent on its secretion. Further studies to address these points will allow a better understanding of the complex role of the role of IL-1 family cytokines in insulin resistance and obesity. 
